Gilead HIV drug prices increase significantly, while Novartis enters a $5.2 billion licensing deal with Argo Biopharmaceutical.
Author: PharmaSignal News Desk
Enveda Biosciences funding reaches $300M to develop drugs for immune and obesity conditions, including atopic dermatitis and asthma.
FDA ultra-rare disease drugs review pathway targets conditions affecting fewer than 1,000 people in the U.S.
Pharma industry executives expect the recent GST rate cut to serve as a booster for contract manufacturers, while on the issue of input tax credit (ITC) — arising from the 18 per tax on APIs — leaders suggest that faster processing of refunds could help to recover the invested capital and ease tax liability.
Cipla Q1 earnings beat forecast, leading to a rise in shares. The financial performance highlights growth in India.
FDA waives trial requirement for Stelera biosimilar, marking a regulatory breakthrough and potentially reducing costs.
Bravehart Hengrui licensing involves a drug for hypertrophic cardiomyopathy, challenging Bristol Myers’ Camzyos in China.
Lilly has temporarily halted UK shipments of Mounjaro until Sept. 1, when new list prices take effect.
Treeline Biosciences, a biotech company founded by Loxo Oncology’s Josh Bilenker and former Novartis executive Jeff Engelman, has announced the advancement of three cancer drugs into Phase 1 clinical trials. This development is supported by a substantial $200 million……
Novartis licenses RNA medicine from Arrowhead in $200M deal